Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2019 | 1 |
2020 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Nat Commun. 2022 Nov 2;13(1):6579. doi: 10.1038/s41467-022-34000-6.
Nat Commun. 2022.
PMID: 36323660
Free PMC article.
CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.
Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, Bullock E, Brambillasca CS, Pulver EM, Nieuwland M, de Rink I, van Diepen F, Klarenbeek S, Kerkhoven R, Brunton VG, Scheele CLGJ, Boelens MC, Jonkers J.
Houthuijzen JM, et al. Among authors: brambillasca cs.
Nat Commun. 2023 Jan 12;14(1):183. doi: 10.1038/s41467-023-35793-w.
Nat Commun. 2023.
PMID: 36635273
Free PMC article.
Item in Clipboard
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA.
Bhin J, et al. Among authors: brambillasca cs.
J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29.
J Exp Med. 2023.
PMID: 37642941
Free PMC article.
Item in Clipboard
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
Caputo S, Grioni M, Brambillasca CS, Monno A, Brevi A, Freschi M, Piras IS, Elia AR, Pieri V, Baccega T, Lombardo A, Galli R, Briganti A, Doglioni C, Jachetti E, Bellone M.
Caputo S, et al. Among authors: brambillasca cs.
Front Immunol. 2020 Sep 10;11:1820. doi: 10.3389/fimmu.2020.01820. eCollection 2020.
Front Immunol. 2020.
PMID: 33013832
Free PMC article.
Item in Clipboard
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J.
Annunziato S, et al. Among authors: brambillasca cs.
Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2.
Nat Commun. 2019.
PMID: 30674894
Free PMC article.
Item in Clipboard
Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.
Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, Calcinotto A, Freschi M, Bachi A, Galli R, Bellone M.
Jachetti E, et al.
Cancer Res. 2015 May 15;75(10):2095-108. doi: 10.1158/0008-5472.CAN-14-2346. Epub 2015 Mar 25.
Cancer Res. 2015.
PMID: 25808872
Item in Clipboard
Cite
Cite